This video briefly summarizes key interim data from the MINERVA study presented at this year’s ARVO congress, held in Seattle, US (Monday 02 May 2016, 09:45-10:00 AM, Program Number 1349). A total of 178 patients were randomized to receive ranibizumab or sham at baseline, and treated pro re nata (PRN). Investigators Lai et al. from the University of Hong Kong reported that ranibizumab had demonstrated superior efficacy versus the sham group, with ranibizumab-treated patients gaining 9.5 ETDRS letters at month 2, and that there were no safety concerns. The investigators concluded that there were visual benefits in treating patients with choroidal neovascularization (CNV) that is not related to age-related macular degeneration (AMD) with ranibizumab.
Ranibizumab in CV pts
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
